Do you want to read an article? Please log in or register.
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
Gynecologic Cancer
RECOMMENDED
Related content
Gynecologic Cancer
The forefront of ovarian cancer therapy: update on PARP inhibitors
Ann Oncol.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S
doi: 10.1016/j.annonc.
Genitourinary Cancer
Use of First-Line PARP Inhibitors in Ovarian Cancer
healthbook TIMES Oncology Hematology
Hasler-Strub U.
doi: 10.36000/hbT.OH.2019.02.006
Gynecologic Cancer
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Cancer Treat Rev.
Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI
doi: 10.1016/j.ctrv.2020.102040.
RECOMMENDED
Breast Cancer
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Tung NM, Zakalik D, Somerfield MR, Hereditary Breast Cancer Guideline Expert Panel.
doi: 10.1200/JCO.21.01532
RECOMMENDED
Gynecologic Cancer
ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol.
Sessa C, Schneider DT, Planchamp F, Baust K, Braicu EI, Concin N, Godzinski J, McCluggage WG, Orbach D, Pautier P, Peccatori FA, Morice P, Calaminus G
doi: 10.1016/S1470-2045(20)30091-7.
Further Publications
Management of Cancer Cachexia: ASCO Guideline
J Clin Oncol.
Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL
doi: 10.1200/JCO.20.00611.
Breast Cancer
Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline
J Clin Oncol
Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, Engel J, Horton JK, King TA, Kornecki A, George R, SenGupta SK, Spears PA, Eisen AF
doi: 10.1200/JCO.21.00934
RECOMMENDED
Gynecologic Cancer
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol.
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR
doi: 10.1016/j.annonc.2020.08.2102.
Gynecologic Cancer
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
J Clin Oncol.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM
doi: 10.1200/JCO.19.02960.